ACADIA Pharmaceuticals Inc.
ACAD
Rangering i aksjer
#4429
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aksjekurs
$20.42
Sist synkronisert: 2026-10-20
Markedsverdi
$3.52B
Endring (1 dag)
3.13%
Endring (1 år)
-3.99%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
Inntekter for ACADIA Pharmaceuticals Inc. (ACAD)
Inntekter i Jun 2026 TTM: $1.14B
Ifølge de nyeste økonomiske rapportene til ACADIA Pharmaceuticals Inc. er selskapets nåværende inntekter (TTM) $1.14B. I 2023 hadde selskapet inntekter på $726.44M en økning sammenlignet med inntektene i 2022, som var $517.24M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for ACADIA Pharmaceuticals Inc. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.14B | 18.88% |
| 2024 | $957.80M | 31.85% |
| 2023 | $726.44M | 40.45% |
| 2022 | $517.24M | 6.83% |
| 2021 | $484.15M | 9.60% |
| 2020 | $441.76M | 30.28% |
| 2019 | $339.08M | 51.50% |
| 2018 | $223.81M | 79.19% |
| 2017 | $124.90M | 620.68% |
| 2016 | $17.33M | 28,311.48% |
| 2015 | $61.00K | -49.17% |
| 2014 | $120.00K | -89.52% |
| 2013 | $1.15M | -76.67% |
| 2012 | $4.91M | 137.40% |
| 2011 | $2.07M | -95.09% |
| 2010 | $42.14M | 558.46% |
| 2009 | $6.40M | 302.45% |
| 2008 | $1.59M | -78.95% |
| 2007 | $7.56M | -7.11% |
| 2006 | $8.13M | -25.77% |
| 2005 | $10.96M | 137.96% |
| 2004 | $4.60M | -37.60% |
| 2003 | $7.38M | 17.57% |
| 2002 | $6.28M | 68.97% |
| 2001 | $3.71M | -13.87% |
| 2000 | $4.31M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 1,008.71% |
US
|
|
| $2.23B | 95.67% |
US
|
|
| $15.74B | 1,282.73% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 428.81% |
NL
|
